| 货号 | 12082-1mg |
| 描述 | Vitamin D aids in the absorption of calcium and has central roles in bone formation and maintenance, hypertension, cancer, and immunity.1,2 1-hydroxy Vitamin D3 is a synthetic prodrug which is converted by cytochrome P450 isoforms to the vitamin D receptor agonist 1,25-dihydroxy vitamin D3in vivo.3,4 Such prodrugs are effective in suppressing the synthesis and secretion of parathyroid hormone in secondary hyperparathyroidism, an action which requires the vitamin D receptor.5,4,6 1-hydroxy Vitamin D3 supports bone growth both in postmenopausal women and in glucocorticoid-induced osteoporosis.7,8 It also provides renal and cardiovascular protection during chronic kidney disease.9,10 |
| 别名 | Alfacalcidol;Bondiol;Etalpha;1-Hydroxycholecalciferol;Oxydevit;Tevabone; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Holick, M.F. Vitamin D deficiency. New England Journal of Medicine 357(3), 266-281 (2007). 2.Peterlik, M.,Boonen, S.,Cross, H.S., et al. Vitamin D and calcium insufficiency-related chronic diseases: An emerging world-wide public health problem. Int.J.Environ.Res.Public Health 6, 2585-2607 (2009). 3.Upton, R.A.,Knutson, J.C.,Bishop, C.W., et al. Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone. Nephrology Dialysis Transplantation 18, 750-758 (2003). 4.Brown, A.J.,Dusso, A.S., and Slatopolsky, E. Vitamin D analogues for secondary hyperparathyroidism. Nephrology Dialysis Transplantation 17, 10-19 (2002). 5.Frazao, J.M.,Chesney, R.W.,Coburn, J.W., et al. Intermittent oral 1α-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. Nephrology Dialysis Transplantation 13, 68-72 (1998). 6.Ritter, C.S., and Brown, A.J. Direct suppression of Pth gene expression by the vitamin D prohormones doxercalciferol and calcidiol requires the vitamin D receptor. Journal of Molecular Endocrinology 46(2), 63-66 (2011). 7.Nuti, R.,Bianchi, G.,Brandi, M.L., et al. Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis. Rheumatology International 26, 445-453 (2006). 8.Pereira, R.M.R.,de Carvalho, J.F.,Paula, A.P., et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev.Bras.Reumatol. 52(4), 569-593 (2012). 9.Gravellone, L.,Rizzo, M.A.,Martina, V., et al. Vitamin D receptor activators and clinical outcomes in chronic kidney disease. Int.J.Nephrol. 2011, (2011). 10.Jorgensen, H.S.,Winther, S.,Povlsen, J.V., et al. Effect of vitamin-D analogue on albuminuria in patients with non-dialysed chronic kidney disease stage 4-5: A retrospective single center study. BMC Nephrol. 13(1), (2012). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥95% |
| 计算分子量 | 400.6 |
| 分子式 | C27H44O2 |
| CAS号 | 41294-56-8 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |